<DOC>
	<DOCNO>NCT01999842</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity different formulation GSK Biologicals ' H7N9 influenza vaccine subject 18 64 year age .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Influenza Vaccine ( ) GSK3206641A GSK3206640A Administered Adults 18 64 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female adult 18 64 year age ( inclusive ) time first study vaccination . Written inform consent obtain subject . Subjects investigator believe comply requirement protocol . Healthy subject establish medical history physical examination . Access consistent mean telephone contact . For subject undergo screen visit : result safety laboratory test obtain screen visit must within reference range . Results repeat test use qualify subject enrolment . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue practice adequate contraception 2 month last dose administer . Presence evidence neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence evidence substance abuse . Diagnosed cancer , treatment cancer within three year . Diagnosed excessive daytime sleepiness , narcolepsy ; history narcolepsy subject 's parent , sibling child . Presence temperature ≥ 38.0ºC ( ≥100.4ºF ) , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid within 30 day prior first dose study vaccine/placebo , cytotoxic , immunosuppressive immunemodifying drug within 6 month first study vaccine/ placebo dose . Any significant disorder coagulation treatment warfarin derivative heparin . An acute evolve neurological disorder Guillain Barré Syndrome within 42 day receipt prior seasonal pandemic influenza vaccine . Administration inactive vaccine within 14 day live attenuated vaccine within 30 day first dose study vaccine/placebo . Planned administration vaccine study vaccine/placebo blood sample Day 42 visit . Previous administration H7 vaccine physicianconfirmed H7 disease . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine/placebo , plan use study period . Receipt immunoglobulins and/or blood product within 90 day first dose study vaccine/placebo , plan administration product study period . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine include history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result first dose study vaccine/placebo . Lactating nursing woman . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Adults</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>H7N9</keyword>
	<keyword>Influenza</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>